Rewiring mTOR signaling in Alzheimer’s disease: emerging mTOR modulators beyond oncology
Bioscience Reports · 17.06.2026 · 46 (6)
DOI: 10.1042/bsr20260203 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioscience Reports, online erschienen am 10.06.2026. Verfasst von Benedikt Jakob Lohnes und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany. Hauptthemen laut MEDLINE: Alzheimer Disease, TOR Serine-Threonine Kinases, MTOR Inhibitors. Die Arbeit nennt 230 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
While Alzheimer’s disease (AD) is the most common cause of dementia, curative treatments remain unavailable. Despite distinct pathologies between AD and cancer, shared dysregulation of the PI3K-AKT-mTOR signaling pathway promotes both disease states. mTOR activity significantly contributes to AD hallmarks, including amyloid-beta production, tau hyperphosphorylation, and altered metabolism and autophagy through mTOR-mediated signaling and downstream targets such as BACE-1, GSK-3β, and AChE. Consequently, mTOR-modulating compounds, demonstrating promising results in oncology, present a viable strategy to potentially halt or reverse AD progression. This review discusses the potential application of 37 mTOR pathway-modulating compounds, many originally developed for cancer treatment, given their shared molecular targets. We systematically classified the compounds based on their origin as marine, plant-derived, structural analogs, and synthetic compounds. This framework reveals a fundamental trade-off, as the structural novelty and pleiotropic effects of natural products are often counterbalanced by poor pharmacokinetics, whereas the pharmacological precision of synthetic compounds is frequently limited by compensatory feedback loops. Furthermore, we analyze translational challenges, including balancing efficacy with toxicity, limitations in blood-brain barrier penetration, and the need for patient stratification using robust biomarkers. We conclude that the most promising therapeutic approach for AD involves synergistically combining natural products with rational synthetic design. Leveraging natural products as a source of novel chemical scaffolds and employing targeted synthetic engineering to overcome their pharmacokinetic limitations, this strategy moves beyond blunt pathway inhibition. Ultimately, this enables a highly nuanced modulation of the mTOR network, providing the basis for future preclinical and clinical drug development in AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Medical Oncology, University Medical Center of the Johannes Gutenberg-University Mainz, 55131 Mainz, Germany.
- Biochemistry & Molecular Biology Laboratory, Department of Biosciences, Manipal University Jaipur, Jaipur-Ajmer Express Highway, Dehmi Kalan, Near GVK Toll Plaza, Jaipur, Rajasthan 303007, India.
- Department of Analytical Chemistry, University of Chemistry & Technology Prague, Prague, Czech Republic.
- Life Sciences Division, Getinge Netherlands, Heertjeslaan 2, 2629 JG Delft, Netherlands.
- Research Center for Immunotherapy (FZI), University Medical Center, Johannes Gutenberg-University, Mainz, 55131 Mainz, Germany.
- Center for Health and Therapeutic Research (CHTR), Manipal University Jaipur, Jaipur-Ajmer Express Highway, Dehmi Kalan, Near GVK Toll Plaza, Jaipur, Rajasthan 303007, India.
ORCID-Profile: Benedikt Jakob Lohnes, Udo Frank Hartwig, Nitesh Kumar Poddar
Zitieren
APA
Lohnes, B. J., Myskova, A., Tyagi, A., Hartwig, U. F., & Poddar, N. K. (2026). Rewiring mTOR signaling in Alzheimer’s disease: emerging mTOR modulators beyond oncology. Bioscience Reports, 46(6). https://doi.org/10.1042/bsr20260203
Vancouver
Lohnes BJ, Myskova A, Tyagi A, Hartwig UF, Poddar NK. Rewiring mTOR signaling in Alzheimer’s disease: emerging mTOR modulators beyond oncology. Bioscience Reports. 2026;46(6). doi:10.1042/bsr20260203
BibTeX
@article{Lohnes2026,
author = {Lohnes, Benedikt Jakob and Myskova, Aneta and Tyagi, Arti and Hartwig, Udo Frank and Poddar, Nitesh Kumar},
title = {Rewiring mTOR signaling in Alzheimer’s disease: emerging mTOR modulators beyond oncology},
journal = {Bioscience Reports},
year = {2026},
volume = {46},
number = {6},
doi = {10.1042/bsr20260203}
}
EUVIMED